Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.

Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, van der Kwast TH, Trapman J.

Cancer Res. 2005 Jul 1;65(13):5730-9.

2.

Physiological functions of Pten in mouse tissues.

Kishimoto H, Hamada K, Saunders M, Backman S, Sasaki T, Nakano T, Mak TW, Suzuki A.

Cell Struct Funct. 2003 Feb;28(1):11-21. Review.

4.

PTEN, more than the AKT pathway.

Blanco-Aparicio C, Renner O, Leal JF, Carnero A.

Carcinogenesis. 2007 Jul;28(7):1379-86. Epub 2007 Mar 6. Review.

5.

PTENless means more.

Stiles B, Groszer M, Wang S, Jiao J, Wu H.

Dev Biol. 2004 Sep 15;273(2):175-84. Review.

6.

Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment.

De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG.

J Cell Biochem. 2004 Feb 15;91(3):459-77. Review.

PMID:
14755677
7.

[Androgens and increased lipogenesis in prostate cancer. Cell biologic and clinical perspectives].

Verhoeven G.

Verh K Acad Geneeskd Belg. 2002;64(3):189-95; discussion 195-6. Review. Dutch.

PMID:
12238242
8.

[Recent advances on molecular pathology of prostate carcinoma].

Niu HL, Tao Y.

Ai Zheng. 2003 May;22(5):552-6. Review. Chinese.

PMID:
12753724
9.

The role of PTEN in the progression and survival of prostate cancer.

Deocampo ND, Huang H, Tindall DJ.

Minerva Endocrinol. 2003 Jun;28(2):145-53. Review.

PMID:
12717346
10.

Functional analysis of the tumour suppressor gene PTEN in murine B cells and keratinocytes.

Suzuki A, Sasaki T, Mak TW, Nakano T.

Biochem Soc Trans. 2004 Apr;32(Pt 2):362-5. Review.

PMID:
15046610
11.

Advances in mouse models of prostate cancer.

Ahmad I, Sansom OJ, Leung HY.

Expert Rev Mol Med. 2008 Jun 9;10:e16. doi: 10.1017/S1462399408000689. Review.

PMID:
18538039
12.

Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD.

Cancer Res. 2004 Mar 15;64(6):2270-305. Review.

13.

Par-4 inducible apoptosis in prostate cancer cells.

Gurumurthy S, Rangnekar VM.

J Cell Biochem. 2004 Feb 15;91(3):504-12. Review.

PMID:
14755681
14.

Primary cell cultures as models of prostate cancer development.

Peehl DM.

Endocr Relat Cancer. 2005 Mar;12(1):19-47. Review.

15.

Akt in prostate cancer: possible role in androgen-independence.

Ghosh PM, Malik S, Bedolla R, Kreisberg JI.

Curr Drug Metab. 2003 Dec;4(6):487-96. Review.

PMID:
14683476
16.

Apoptosis in prostate cancer: progressive and therapeutic implications (Review).

Wang G, Reed E, Li QQ.

Int J Mol Med. 2004 Jul;14(1):23-34. Review.

PMID:
15202013
17.

The significance of key regulators of apoptosis in the development and prognosis of prostate carcinoma. II. Products of suppressor genes Rb and PTEN, CDKI, Fas.

Knillová J, Kolár Z, Hlobilková A.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2003 Nov;147(1):11-7. Review.

18.
19.

Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer.

Patierno SR, Manyak MJ, Fernandez PM, Baker A, Weeraratna AT, Chou DS, Szlyk G, Geib KS, Walsh C, Patteras J.

Clin Prostate Cancer. 2002 Sep;1(2):118-24. Review.

PMID:
15046703
20.

Cell-cycle dysregulation and the molecular mechanisms of prostate cancer.

Amanatullah DF, Reutens AT, Zafonte BT, Fu M, Mani S, Pestell RG.

Front Biosci. 2000 Apr 1;5:D372-90. Review.

PMID:
10762592
Items per page

Supplemental Content

Write to the Help Desk